MetaCap

Lexeo Therapeutics (LXEO) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ocugen (OCGN) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 33.8% versus a loss of 67.3%. Ocugen is the larger company by market cap ($260.6 million vs $245.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LXEO-67.33%OCGN-33.80%
+123%+21%-80%
Nov 21, 20251 yearNov 20, 2026
LXEO-70.55%OCGN+99.45%
+575%+232%-112%
Oct 30, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LXEO versus OCGN key metrics
MetricLXEOOCGN
Share price$2.96$0.7679
Market cap$245.05M$260.55M
1-day change+0.34%+4.79%
YTD return-70.19%-43.12%
1-year return-67.33%-33.80%
5-year return—-88.09%
EPS (TTM)$-1.13$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.41M
Revenue growth (YoY)—+8.83%
Net income (latest FY)$-100.00M$-67.85M
Operating margin—-1425.70%
Net margin—-1537.41%
52-week high$10.99$2.73
52-week low$2.55$0.691
Distance from 52-week high-73.07%-71.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+748.31%+1484.84%
Average volume1.98M7.34M
Shares outstanding82.79M339.31M
Employees68116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OCGN has outperformed LXEO by 33.5 percentage points over the past year.

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

LXEO vs OCGN FAQ

Which is bigger, Lexeo Therapeutics or Ocugen?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $245.05M for Lexeo Therapeutics (LXEO).

Which stock has performed better over the past year, LXEO or OCGN?

OCGN returned -33.80% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Lexeo Therapeutics and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons